A specialty chemicals maker producing Tyvek protective garments, water-filtration membranes, medical device components, and building insulation. Founded in 1802 by French-American chemist Eleuthère Irénée du Pont, who set up a gunpowder mill along Delaware's Brandywine River. Fun fact: Tyvek, its famously tough paper-like fabric, was discovered by accident in 1955 when a researcher spotted a mysterious "white fluff" spilling from a lab pipe.
Net sales of $1.8 billion, up 4% (organic sales up 4%) versus year-ago period.
Show detailsHide details
GAAP income from continuing operations of $191 million; operating EBITDA of $448 million.
GAAP EPS from continuing operations of $1.37; adjusted EPS of $1.88.
Cash provided by operating activities from continuing operations of $400 million; transaction-adjusted free cash flow of $326 million (127% conversion).
DuPont effects 1-for-3 reverse stock split effective June 24, 2026
DuPont de Nemours, Inc. filed a Certificate of Amendment to its Third Amended and Restated Certificate of Incorporation with the Delaware Secretary of State on June 23, 2026.
Show detailsHide details
The amendment implements a 1-for-3 reverse stock split of common stock and proportionally reduces authorized shares, effective at 12:01 a.m. ET on June 24, 2026.
Stockholders approved the reverse split on May 21, 2026, and the Board of Directors approved it on May 26, 2026.
A restated certificate of incorporation was filed to reflect the amendment, effective at 12:02 a.m. ET on June 24, 2026.
Common stock continues trading on NYSE under ticker 'DD'; new CUSIP is 26614N 201.
3.03 Material Modification to Rights of Security Holders · 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · 9.01 Financial Statements and Exhibits
At DuPont's May 21, 2026 Annual Meeting, stockholders elected 10 director nominees and approved executive compensation, ratification of PricewaterhouseCoopers as auditor, and a reverse stock split amendment.
Show detailsHide details
The board approved a 1-for-3 reverse stock split, reducing authorized shares from 1,666,666,667 to 555,555,556, effective 12:01 a.m. ET on June 24, 2026.
The reverse stock split will combine every three shares into one, with cash paid for fractional shares, and trading will continue under ticker 'DD' with a new CUSIP.
DuPont reaffirmed 2026 guidance, presenting adjusted EPS on a split-adjusted basis: ~$1.75 for Q2 and $7.02-$7.16 for full year 2026.
The report was filed under Items 5.07, 7.01, and 9.01 to disclose shareholder vote results, the reverse stock split announcement, and the related press release exhibit.
5.07 Submission of Matters to a Vote of Security Holders · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits
DuPont plans reverse stock split of 1-for-2 to 1-for-4, subject to shareholder approval
On March 18, 2026, DuPont announced plans to seek stockholder approval for a reverse stock split of its common stock at a ratio between 1-for-2 and 1-for-4, with the exact ratio to be set later by the Board of Directors.
Show detailsHide details
The proposal will be voted on at the Annual Meeting of Stockholders on May 21, 2026; the record date for voting is March 30, 2026.
If effected, the Certificate of Incorporation will be amended to reduce the number of authorized shares proportionally to the selected reverse stock split ratio.
The reverse stock split will not affect stockholder voting rights, business operations, or outstanding indebtedness.
The Board may delay or abandon the reverse stock split at any time before it becomes effective, even if approved by stockholders.
8.01 Other Events · 9.01 Financial Statements and Exhibits
DuPont expects to close sale of aramids business to Arclin on April 1, 2026.
All regulatory conditions to close the sale transaction were satisfied as of March 10, 2026.
Show detailsHide details
DuPont de Nemours, Inc. announced it expects to close the previously announced sale of its aramids business (Kevlar® and Nomex®) to Arclin on April 1, 2026.
The buyer is ARC Falcon Holdings, L.P. and New Arclin U.S. Holding Corp., a wholly-owned subsidiary of Holdings.
The disclosure was furnished under Item 7.01 Regulation FD Disclosure and is not deemed filed for SEC purposes.
The report includes a cautionary statement about forward-looking statements regarding the transaction.